BXA0 Stock Overview
Engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, dermocosmetic, and healthcare products to physicians and pharmacists in Greece and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Lavipharm S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.73 |
| 52 Week High | €1.02 |
| 52 Week Low | €0.58 |
| Beta | 0.88 |
| 11 Month Change | -3.29% |
| 3 Month Change | -4.18% |
| 1 Year Change | 11.21% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 2.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| BXA0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -0.7% | 3.1% | 4.5% |
| 1Y | 11.2% | -12.1% | 13.4% |
Return vs Industry: BXA0 exceeded the German Pharmaceuticals industry which returned -12.1% over the past year.
Return vs Market: BXA0 underperformed the German Market which returned 13.4% over the past year.
Price Volatility
| BXA0 volatility | |
|---|---|
| BXA0 Average Weekly Movement | 10.8% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BXA0's share price has been volatile over the past 3 months.
Volatility Over Time: BXA0's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1911 | 300 | n/a | lavipharm.com |
Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, dermocosmetic, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and over the counter (OTC) products, as well as LIFELAB CBD.
Lavipharm S.A. Fundamentals Summary
| BXA0 fundamental statistics | |
|---|---|
| Market cap | €138.16m |
| Earnings (TTM) | €7.13m |
| Revenue (TTM) | €51.34m |
19.4x
P/E Ratio2.7x
P/S RatioIs BXA0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BXA0 income statement (TTM) | |
|---|---|
| Revenue | €51.34m |
| Cost of Revenue | €28.10m |
| Gross Profit | €23.25m |
| Other Expenses | €16.12m |
| Earnings | €7.13m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.042 |
| Gross Margin | 45.27% |
| Net Profit Margin | 13.88% |
| Debt/Equity Ratio | 39.2% |
How did BXA0 perform over the long term?
See historical performance and comparison